ENA to Smith (Sm) Antibody
Part of Immune System

The ENA (Extractable Nuclear Antigens) to Smith (Sm) antibody test plays a pivotal role in the field of autoimmune diagnostics, particularly in the context of systemic lupus erythematosus (SLE). Smith antibodies are a subset of antinuclear antibodies (ANAs), specifically targeting proteins found within the cell nucleus, known as Sm antigens. These antigens are integral to the splicing of pre-mRNA, making them vital for cell function. In autoimmune conditions like SLE, the body's immune system mistakenly targets its own tissues, with Smith antibodies being one of the markers of this aberrant immune response. The presence of Smith antibodies is considered highly specific for SLE; while they are not found in all patients with SLE, their presence is rarely observed in other diseases. This specificity makes the ENA to Sm antibody test an invaluable tool in the differential diagnosis of SLE, distinguishing it from other autoimmune disorders that may present with similar symptoms. Testing for Smith antibodies is typically conducted through blood serum analysis using techniques like enzyme-linked immunosorbent assay (ELISA) or immunofluorescence. A positive test result for Smith antibodies, especially when correlated with clinical symptoms and other laboratory findings, can significantly aid in the diagnosis of SLE. Moreover, monitoring the levels of these antibodies can provide insights into the disease's progression and response to treatment. Understanding the significance of ENA to Smith antibodies in SLE is essential for both patients and healthcare professionals. It guides diagnosis, informs treatment strategies, and enhances the understanding of the disease process. For individuals undergoing evaluation for autoimmune disorders, especially those with symptoms suggestive of SLE, discussing the possibility of Smith antibody testing with a healthcare provider can be a critical step in their diagnostic journey.

Optimal range 0 – 40 AU/mL Learn more
ENA-6 Reflexed
Part of Immune System

The ENA-6 Reflexed test is a blood test used to help diagnose autoimmune diseases, particularly those that affect the connective tissues, such as Systemic Lupus Erythematosus (SLE), Sjögren's syndrome, scleroderma, and polymyositis. "ENA" stands for Extractable Nuclear Antigens, which are proteins found inside the nucleus of cells that can become targets of the immune system in autoimmune diseases. The "6" refers to six specific antigens included in this panel: SS-A (Ro), SS-B (La), Sm, RNP, Scl-70, and Jo-1. Each of these antigens is associated with different autoimmune conditions, and identifying antibodies against them can provide valuable clues for diagnosis. For example, antibodies against SS-A and SS-B are often found in patients with Sjögren's syndrome, while antibodies against Sm are highly specific for SLE. When a doctor orders an ENA-6 Reflexed test, they are looking to see if a patient’s immune system is producing antibodies against any of these six antigens. If the initial screening test (typically an antinuclear antibody, or ANA test) comes back positive, the ENA-6 test is automatically "reflexed" or performed next to further pinpoint which specific antibodies are present. This step-by-step approach helps doctors narrow down the possible autoimmune diseases a patient might have. By understanding which antibodies are present, doctors can tailor treatment plans more effectively and monitor disease progression more accurately. In summary, the ENA-6 Reflexed test is a critical tool in the diagnosis and management of various autoimmune diseases, providing specific information that helps guide patient care.

Learn more
Endomysial Antibody Scr (IgA) w/Refl to Titer
Blood
Part of Celiac Comprehensive Panel

The Endomysial Antibody Screen (IgA) with Reflex to Titer is a specialized blood test that is primarily used to diagnose autoimmune conditions such as celiac disease and dermatitis herpetiformis. This test detects the presence of Endomysial Antibodies (EMA) of the IgA type in the bloodstream. An initial screening is performed, and if it yields a positive or indeterminate result, a reflex to titer is conducted to measure the antibody levels more precisely. An elevated titer of IgA-EMA is highly specific for celiac disease and dermatitis herpetiformis. In the context of celiac disease, an elevated titer indicates an abnormal immune response to gluten, which can lead to damage in the lining of the small intestine. This damage compromises nutrient absorption and can result in various gastrointestinal and systemic symptoms. Therefore, the Endomysial Antibody Screen with Reflex to Titer plays a crucial role in the diagnosis of these autoimmune conditions, helping healthcare providers identify patients who need further evaluation and management, including dietary changes to avoid gluten-containing foods. It is an essential tool for diagnosing and managing gluten-related disorders effectively.

Learn more